Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike.

Trattnig N, Blaukopf M, Bruxelle JF, Pantophlet R, Kosma P.

J Am Chem Soc. 2019 May 15;141(19):7946-7954. doi: 10.1021/jacs.9b02872. Epub 2019 Apr 30.

2.

Comparative Antigenicity of Thiourea and Adipic Amide Linked Neoglycoconjugates Containing Modified Oligomannose Epitopes for the Carbohydrate-Specific anti-HIV Antibody 2G12.

Trattnig N, Mayrhofer P, Kunert R, Mach L, Pantophlet R, Kosma P.

Bioconjug Chem. 2019 Jan 16;30(1):70-82. doi: 10.1021/acs.bioconjchem.8b00731. Epub 2018 Dec 28.

3.

Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.

Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P.

Nat Commun. 2017 Nov 17;8(1):1601. doi: 10.1038/s41467-017-01640-y.

4.

Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides.

Trattnig N, Farcet JB, Gritsch P, Christler A, Pantophlet R, Kosma P.

J Org Chem. 2017 Dec 1;82(23):12346-12358. doi: 10.1021/acs.joc.7b02172. Epub 2017 Oct 26.

5.

Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.

Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R, Clark BE, Auyeung K, Bhattacharya J, Vajpayee M, Wig N, Pantophlet R, Luthra K.

PLoS One. 2015 May 11;10(5):e0125575. doi: 10.1371/journal.pone.0125575. eCollection 2015.

6.

Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose.

Stanfield RL, De Castro C, Marzaioli AM, Wilson IA, Pantophlet R.

Glycobiology. 2015 Apr;25(4):412-9. doi: 10.1093/glycob/cwu123. Epub 2014 Nov 7.

7.

The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

Manhas S, Chau D, Rempel C, Clark BE, Auyeung K, Pantophlet R.

Virology. 2014 Aug;462-463:98-106. doi: 10.1016/j.virol.2014.05.034. Epub 2014 Jun 25.

8.

2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR.

J Virol. 2013 Feb;87(4):2234-41. doi: 10.1128/JVI.02820-12. Epub 2012 Dec 5.

9.

A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design.

Clark BE, Auyeung K, Fregolino E, Parrilli M, Lanzetta R, De Castro C, Pantophlet R.

Chem Biol. 2012 Feb 24;19(2):254-63. doi: 10.1016/j.chembiol.2011.12.019.

10.

Complex binding sites made to order.

Scott JK, Pantophlet R, Craig L.

Nat Biotechnol. 2012 Feb 8;30(2):154-5. doi: 10.1038/nbt.2118. No abstract available.

PMID:
22318033
11.

An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Ahmed FK, Clark BE, Burton DR, Pantophlet R.

Vaccine. 2012 Jan 20;30(5):922-30. doi: 10.1016/j.vaccine.2011.11.089. Epub 2011 Dec 4.

12.

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.

Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L.

J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.

13.

Antibody epitope exposure and neutralization of HIV-1.

Pantophlet R.

Curr Pharm Des. 2010;16(33):3729-43. Review.

PMID:
21128886
14.

Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR.

Chem Biol. 2010 Apr 23;17(4):357-70. doi: 10.1016/j.chembiol.2010.03.012.

15.

Report on the AIDS Vaccine 2008 Conference.

Alter G, Ananworanich J, Pantophlet R, Rybicki EP, Buonaguro L.

Hum Vaccin. 2009 Mar;5(3):119-25. Epub 2009 Mar 8.

PMID:
19202348
16.

The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR.

J Virol. 2009 Feb;83(4):1649-59. doi: 10.1128/JVI.02046-08. Epub 2008 Nov 26.

17.

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR.

Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.

18.

An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.

Cohen C, Forzan M, Sproat B, Pantophlet R, McGowan I, Burton D, James W.

Virology. 2008 Nov 10;381(1):46-54. doi: 10.1016/j.virol.2008.08.025. Epub 2008 Sep 17.

19.

A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.

Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR.

J Virol. 2008 Jul;82(13):6359-68. doi: 10.1128/JVI.00293-08. Epub 2008 Apr 23.

20.

Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA.

J Mol Biol. 2008 Jan 25;375(4):969-78. Epub 2007 Nov 13.

21.
22.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

23.

Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.

Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, Wilson IA.

J Mol Biol. 2007 Jun 8;369(3):696-709. Epub 2007 Jan 27.

24.

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR.

Virology. 2007 Aug 1;364(2):441-53. Epub 2007 Apr 6.

25.

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR.

J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.

26.

GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.

PMID:
16551265
27.

Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia.

Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T.

Am J Respir Crit Care Med. 2006 Jan 1;173(1):122-9. Epub 2005 Oct 6.

PMID:
16210672
28.

Comparing antigenicity and immunogenicity of engineered gp120.

Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR.

J Virol. 2005 Oct;79(19):12148-63.

29.

A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation.

O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, Gonzalez EJ, Jacoby TJ, Yant L, Piontkivska H, Pantophlet R, Burton DR, Rehrauer WM, Wilson N, Hughes AL, Watkins DI.

J Virol. 2004 Dec;78(24):14012-22.

30.

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.

Pantophlet R, Wilson IA, Burton DR.

Protein Eng Des Sel. 2004 Oct;17(10):749-58. Epub 2004 Nov 12.

PMID:
15542540
32.

Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM.

Biochemistry. 2004 Feb 24;43(7):1928-38.

PMID:
14967033
33.

Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X.

Biochemistry. 2004 Feb 17;43(6):1410-7.

PMID:
14769016
34.

The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12.

Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Calarese D, Stanfield R, Wilson IA, Katinger H, Dwek RA, Burton DR, Rudd PM.

Adv Exp Med Biol. 2003;535:205-18. No abstract available.

PMID:
14714897
35.

Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design.

Saphire EO, Stanfield RL, Crispin MD, Morris G, Zwick MB, Pantophlet RA, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA.

Adv Exp Med Biol. 2003;535:55-66. Review. No abstract available.

PMID:
14714888
36.

Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies.

Pantophlet R, Burton DR.

Trends Mol Med. 2003 Nov;9(11):468-73.

PMID:
14604823
37.
38.
39.

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR.

J Virol. 2002 Jul;76(14):7306-21.

41.
42.

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA.

Science. 2001 Aug 10;293(5532):1155-9.

44.
48.
49.

Specificity of rabbit antisera against lipopolysaccharide of Acinetobacter.

Pantophlet R, Brade L, Dijkshoorn L, Brade H.

J Clin Microbiol. 1998 May;36(5):1245-50.

50.

Supplemental Content

Loading ...
Support Center